Xeris’ GVOKE (glucagon) Receives FDA’s Approval as The First Ready-To-Use Stable Liquid Glucagon for Severe Hypoglycemia

 Xeris’ GVOKE (glucagon) Receives FDA’s Approval as The First Ready-To-Use Stable Liquid Glucagon for Severe Hypoglycemia

Xeris’ GVOKE (glucagon) Receives FDA’s Approval as The First Ready-To-Use Stable Liquid Glucagon for Severe Hypoglycemia Xeris’ GVOKE (glucagon) Receives FDA’s Approval as The First Ready-To-Use Stable Liquid Glucagon for Severe Hypoglycemia

Shots:

  •  The approval is based on three P-III studies (NCT02656069, NCT03091673, NCT03439072) assessing GVOKE vs conventional glucagon emergency kits in adults and children aged ≥2yrs. with T1D
  • The studies demonstrated 100% treatment success in children & 99% in adults. Usability research assessing GVOKE PFS and GVOKE HypoPen resulted in ~100% success rate in administering a full dose of glucagon utilizing 2-step administration process
  • GVOKE is the first premixed, prefilled, premeasured liquid glucagon administered via prefilled syringe (GVOKE PFS) or auto-injector (GVOKE HypoPen) in patients with severe hypoglycemic events and will be available in 0.5 mg/0.1 mL dose and a 1 mg/0.2 mL dose for pediatric and adolescent/adult patients respectively

Click here to­ read full press release/ article | Ref: Xeris Pharmaceutical | Image: Xeris Pharmaceutical

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post